Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is spearheading the ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY) is one of the Reddit Stocks with the Highest Upside Potential. On August 7, the company ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...